Results 181 to 190 of about 3,353 (212)
Some of the next articles are maybe not open access.
European Journal of Pharmaceutics and Biopharmaceutics
Bosentan monohydrate (BOS) is the most preferred molecule for treating the rare pulmonary arterial hypertension (PAH) disease. BOS shows low solubility and high variability when administered orally. This study evaluated the pharmacodynamic biodistribution, echocardiography, and histology results of BOS-loaded SNEDDS and BOS-loaded S-SNEDDS tablets ...
Duygu YILMAZ USTA +7 more
openaire +2 more sources
Bosentan monohydrate (BOS) is the most preferred molecule for treating the rare pulmonary arterial hypertension (PAH) disease. BOS shows low solubility and high variability when administered orally. This study evaluated the pharmacodynamic biodistribution, echocardiography, and histology results of BOS-loaded SNEDDS and BOS-loaded S-SNEDDS tablets ...
Duygu YILMAZ USTA +7 more
openaire +2 more sources
Fortifying SNEDDS with Hybrid Technologies: Present and Future Prospects
Current NanomedicineSelf-nano-emulsifying drug delivery systems (SNEDDS) have gained attention in recentyears as an effective approach for improving the solubility and oral bioavailability of poorlywater-soluble drugs. However, there have been reports of drawbacks such as low drug loading,limited stability and variability in ...
Nithya Shanthi +6 more
openaire +1 more source
3D printed capsule shells for personalized dosing of cyclosporine-loaded SNEDDS
International Journal of PharmaceuticsCyclosporine (CsA) is a potent immunosuppressant agent that has been used since 1980 for the treatment of various autoimmune diseases and is extensively used to enhance the survival rate of patients and grafts following organ transplant surgeries. CsA is a poorly soluble drug with a narrow therapeutic window and inter-subject variability, which can ...
Mohammed S. Algahtani +4 more
openaire +2 more sources